| 1 |
35577753 | SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. | 2022 Jul |
1 |
| 2 |
33790890 | The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. | 2021 |
1 |
| 3 |
29468637 | Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. | 2019 Feb |
1 |
| 4 |
31467081 | Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells. | 2019 Oct 18 |
1 |
| 5 |
28971495 | Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. | 2018 Feb |
1 |
| 6 |
27061924 | Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia. | 2017 May |
1 |
| 7 |
28125433 | PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. | 2017 Apr |
1 |
| 8 |
28187444 | Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. | 2017 Mar 7 |
1 |
| 9 |
28782884 | Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. | 2017 Sep |
1 |
| 10 |
29222275 | The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. | 2017 Dec 8 |
1 |
| 11 |
29250930 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia. | 2017 Dec |
1 |
| 12 |
27040702 | Initial therapy of chronic lymphocytic leukemia. | 2016 Apr |
1 |
| 13 |
27913471 | Sequencing of chronic lymphocytic leukemia therapies. | 2016 Dec 2 |
1 |
| 14 |
25908509 | Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. | 2015 May |
1 |
| 15 |
26062943 | Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. | 2015 |
1 |
| 16 |
26628631 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. | 2015 Dec |
1 |
| 17 |
26637744 | Management of prolymphocytic leukemia. | 2015 |
1 |
| 18 |
26637745 | Prognostic markers and standard management of chronic lymphocytic leukemia. | 2015 |
1 |